Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA has announced FDA clearance for a Phase 1 clinical study of IPH4502, a novel antibody drug conjugate aimed at treating solid tumors with Nectin-4 expression. The eagerly anticipated study will explore the safety, tolerability, and preliminary efficacy of IPH4502 in a variety of cancers, including urothelial and breast cancer. This milestone marks Innate’s first ADC program to enter clinical trials, offering potential new treatment options for patients with Nectin-4 expressing cancers.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.